| Lightcalls.com |
|
|
![]() |
Ginkgo (Ginkgo biloba), a preeminen...Ginkgo (Ginkgo biloba), a preeminent herb from traditional Chinese medicine, ranks among the mostly the most thoroughly researched, and best-selling, herbal remedies. Of the more than 250 clinical and experimental trials that have been directioned to date, involving gingko extracts, the majority demonstrate that gingko provides a wide range of health benefits, including acting as an antioxidant, enhancing mental acuity and memory, preventing kin clumping improving blood circulation (especial to the brain and exrtemities), and treating any types of hearing loss. A modern study, continuing in this spirit of research, demonstrates that ginkgo goe beyond preserving mental function and may actually suppres or overturn some of the symptoms of Alzheimer's disease. Solid scientific background: Alzheimer's and demetia "The scientific background of this plant extract is extensive; it goe back at least 20 years in Europe Of course, many of these prior studies did not address dementia, if it be not that there are several that address memory disturbance of the somewhat advanced in life a condition known as cerebral insufficiency. Our reflection is the first to expect specifically at dementia and Alzheimer's disease," Pierre LeBars, MD PhD explained in an interview. LeBars is director of the strange York Institute for Medical Research and the lead author of the recently made known study detailing the potential character of ginkgo for the treatment of Alzheimer's disease. What LeBars' reflection found was certainly impressive: nearly one-third of Alzheimer's patients taking ginkgo counterparts showed improvements in cognitive function. The thought tracked the mental function of 327 patients with dementia (caused according to either Alzheimer's disease or stroke) and randomly assigned them to take either ginkgo complements or look-alike placebo pills each day for one year. The ginkgo counterparts provided 120 mg of a standardized concentrated extract known as EGb The patients were evaluated with three assessment tools commonly used for Alzheimer's patients. First, cognitive impairment was assessed with the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog). other daily living and social behavior was assessed with the Geriatric Evaluation on Relative's Rating Instrument (GERRI). And third, general psychopathology was measured from the Clinical Global Impression of Change (CGIC). Taking the standard results separately, the first ordeal -- the ADAS assessment -- showed that almost the same out of three of the patients in the ginkgo dispose improved in this cognitive scoring. Meanwhile, the placebo assign places to showed a worsening of symptoms according to the ADAS scale, which was to be look forward toed with Alzheimer's patients. In the secondary test, the GERRI score, which is based in succession the family perception of the patient's health status, the family members were able to discover appreciable changes in patient behavior, ability, and cognition for those in the gingko group Finally, in the CGIC, which is based in succession the physician's impressions of the patient, the gingko dispose did not show a relevant change compared to the placebo assign places to Overall, it was found that patients in the placebo assign places to showed cognitive deterioration. However, in the collection treated with the ginkgo extract, this deterioration was arrested after six month of supplementation. Furthermore, and this is the impressive part, in approximately one-third of those in the ginkgo-treated assign places to there appeared to have been more [i]or[/i] less improvement of the cognitive process "I am completely amazed with the eventuates of this study," confided LeBars, "because the patients treated with ginkgo not merely had the progression of their disease arrested, if it be not that they actually showed improvements in 29 percent of the persons This is absolutely incredible to view an improvement in Alzheimer's patients." Antioxidative properties are a link to health Ongoing scientific research continues to investigate the mechanism on which ginkgo provides health benefits. The now passing consensus is that ginkgo's main forces are related to its antioxidative properties. This is consistent with the benefits seen in Alzheimer's patients, since free-radical damage is known to be current in Alzheimer's disease. When asked whether he would attract favor to ginkgo supplements as part of a treatment protocol for Alzheimer's disease, LeBars commented: "After the diagnosis is confirmed as Alzheimer's, and keeping in mind that hereafter research may provide some clarification, it does make thinking principle to supplement with ginkgo. Of course, this is in addition to the treatments already available and used in standard practice." REFERENCE LeBars, PL Katz, MM Berman, N et al. "A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia," J Am M Assoc 278(:16):1327-1332 1997 Victoria Dolby, MPH is a health and nutrition writer who lives in Oregon. She takes a comprehensive await at the history and health benefits of fresh tea in The Green Tea part (Aver),, 1998). Ask your retailer to call: (800) 548-5757 COPYRIGHT 1998 PRIMEDIA Intertec, a PRIMEDIA Company. All Rights Reserved |
![]() |
Other Articles
-Morphotek will collaborat...-Eksigent Technologies nam... -The benefits of outsourci... -Sartorius Corporation ... -In our previous column, w... -Efoora appointed Michael ... -Affymax appointed Anne-Ma... -Traditionally, continuous... -New Brunswick Scientific ... -The German-American firm ... -Don G. Burstyn, formerly ... -American patients are mor... -Summary Prior to va... -BioPharm Editorial Adviso... -Australia agreed to spend... -The Biotechnology Industr... -Ambion, The RNA Company i... -Therapies based on living... -A recent survey found tha... -ViroLogic will acquire Ac... -Cardinal Health named Joh... -One of the greatest chall... -As the president of a sma... -Sweden-based Biovitrum wi... -Nanogen appointed David L... -The Experion Process Know... -Although biomedical resea... -The Supreme Court of Cana... -Netherlands-based DSM Bio... -David A. Smoller joined S... -A few months ago, I wrote... -Panacos Pharmaceuticals w... -Karen K. Vaccaro will res... -Acceleron Pharma appointe... -Two quarterly meetings of... -Illinois-based Abbot Labo... -FKI Logistics announced t... -The following corrections... -It its widest definition,... -UK-based Xcellsyz will li... -Andrew P. Aromando joined... -Invitrogen's comprehensiv... -Last month, we described ... -The Swiss life sciences c... -Protein Design Labs (PDL)... -Model It HNMR, the newest... -Tech transfer, like chang... -QLT and Atrix Laboratorie... -Dendreon announced Christ... -Baxter Pharmaceutical Sol... -The biopharmaceutical ind... -GlaxoSmithKline announced... -Montreal-based Caprion Ph... -Xenova Group recently ann... -Cole-Parmer's new 192-pag... -Over the last decade ther... -Benchmark your facility p... -As biotechnology organiza... -Frederick D. Sancillo, fo... -Insmed acquired a recombi... -Baxter Pharmaceutical Sol... -Model It HNMR, the newest... -DA's regulation 21 CFR Pa... -Robert P. Ryan joined Ath... -A new report from Busines... -Biotest offers a complete... -Swagelok offers a brochur... -Partnering is a global ph... -Human Genome Sciences CEO... -Shorten the process devel... -The licensure of biotechn... -Rodger Currie joined Amge... -The GEA Filtration Model ... -A multi-channel chemistry... -From June 6-9, San Franci... -Skanska USA Building Inc.... -New Brunswick Scientific'... -AVI BioPharma appointed P... -Ambion, The RNA Company, ... -"If you want to be a... -Xcellerex appointed Susan... -Researchers identified th... -Cool Spring Business Park... -In October 2003, Shenzhen... -Laureate Pharma appointed... -After a 6-5 vote by Calif... -QSourcing, a service of Q... -The recent discovery of &... -Affymax added Douglas L. ... -USDA recently approved tw... -BioPharm International is... -Serologicals has released... -This document by Shenzhen... -Robert Bronstein joined A... -Gloucester Gains Fujisawa... -With more than 30 years o... -Pall's SUPRAdisc II depth... -In today's competitive ma... -Protein Design Labs repor... -Charles A. Rice will repl... -AstraZeneca's Faslodex (f... |
| . |